Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (47)

Search Parameters:
Authors = Maciej Lesiak

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
14 pages, 502 KiB  
Article
Pre-Procedural Use of Levosimendan in High-Risk ACS-PCI Patients with Reduced Left Ventricle Ejection Fraction—Short-Term Outcomes
by Karol Turkiewicz, Jan Jakub Kulczycki, Piotr Rola, Szymon Włodarczak, Mateusz Barycki, Piotr Włodarczak, Łukasz Furtan, Paweł Kozak, Adrian Doroszko, Waldemar Banasiak, Maciej Lesiak and Adrian Włodarczak
J. Clin. Med. 2025, 14(8), 2761; https://doi.org/10.3390/jcm14082761 - 17 Apr 2025
Viewed by 432
Abstract
Background/Objectives: Current evidence suggests that levosimendan may have a beneficial effect in the treatment of acute heart failure (AHF) or cardiogenic shock following primary percutaneous coronary intervention (PCI). However, there is a paucity of data on the use of levosimendan prior to PCI. [...] Read more.
Background/Objectives: Current evidence suggests that levosimendan may have a beneficial effect in the treatment of acute heart failure (AHF) or cardiogenic shock following primary percutaneous coronary intervention (PCI). However, there is a paucity of data on the use of levosimendan prior to PCI. Therefore, our pilot study aimed to assess the short-term prognosis of a new therapeutic protocol involving preprocedural infusion of levosimendan in patients with reduced left ventricular ejection fraction undergoing high-risk PCI for acute coronary syndrome (ACS). Methods: The study is a retrospective observational study, and the population includes all subjects who received levosimendan infusion prior to high-risk PCI for ACS. Subjects requiring urgent revascularization (cardiogenic shock, cardiac arrest) or with mechanical complications of ACS were excluded. Results: The study cohort consisted of 90 subjects, predominantly men (91.1%) with significantly reduced left ventricular function (28.7% (12)) and advanced coronary artery disease, mean SYNTAX Score 25.8 (19.3–33). During in-hospital follow-up, we observed 2 primary outcomes—death. The major adverse cardiac and cerebrovascular events (MACCE) rate was 7.8%. Two clinical adverse events that did not lead to discontinuation were observed during the in-hospital period. Both were related to hypotension. Conclusions: In short-term observation, novel therapeutic approach in the management of high-risk PCI in ACS patients—pre-procedural levosimendan—was a relatively safe approach. No significant adverse events were reported. Full article
(This article belongs to the Section Cardiology)
Show Figures

Graphical abstract

13 pages, 264 KiB  
Review
Transcatheter Aortic Valve Implantation in Patients with Previous Mitral Valve Surgery—Review
by Anna Olasińska-Wiśniewska, Marcin Misterski, Marek Grygier, Janusz Konstanty-Kalandyk, Tomasz Urbanowicz, Maciej Lesiak, Marek Jemielity and Maciej Dąbrowski
J. Clin. Med. 2025, 14(3), 735; https://doi.org/10.3390/jcm14030735 - 23 Jan 2025
Cited by 1 | Viewed by 1069
Abstract
Transcatheter aortic valve implantation (TAVI) has become an optimal alternative in selected groups of patients and evolved from procedures in non-option patients to lower-risk-profile patients. One of its main indications is previous cardiac surgery, since redo-intervention is burdened with a higher risk of [...] Read more.
Transcatheter aortic valve implantation (TAVI) has become an optimal alternative in selected groups of patients and evolved from procedures in non-option patients to lower-risk-profile patients. One of its main indications is previous cardiac surgery, since redo-intervention is burdened with a higher risk of complications. However, TAVI after mitral valve surgery may raise concerns due to potential interference with the mitral prosthesis or ring during or after the procedure. The present paper reviews the current knowledge, including possible complications and procedural aspects. Full article
(This article belongs to the Section Cardiology)
12 pages, 908 KiB  
Article
One-Year Prognosis for Patients Diagnosed with Acute Coronary Syndrome Compared to Those with Chronic Coronary Syndrome Following Complex Coronary Procedures
by Patrycja Woźniak, Konrad Stępień, Wojciech Wańha, Anna Smukowska-Gorynia, Aleksander Araszkiewicz, Maciej Lesiak, Weronika Jędraszak, Tatiana Mularek-Kubzdela and Sylwia Iwańczyk
J. Clin. Med. 2025, 14(3), 730; https://doi.org/10.3390/jcm14030730 - 23 Jan 2025
Viewed by 1074
Abstract
Background: Acute coronary syndrome (ACS) remains the primary cause of mortality worldwide. Performing complex coronary intervention in patients with ACS is considered a significant factor for worsening prognosis. This study aimed to evaluate the prognosis of patients with ACS treated with complex procedures [...] Read more.
Background: Acute coronary syndrome (ACS) remains the primary cause of mortality worldwide. Performing complex coronary intervention in patients with ACS is considered a significant factor for worsening prognosis. This study aimed to evaluate the prognosis of patients with ACS treated with complex procedures compared to patients with chronic coronary syndrome (CCS). Methods: Among 980 patients from the Polish Complex Registry, we enrolled 829 consecutive patients who underwent complex percutaneous coronary intervention (PCI) for acute or chronic coronary syndrome with a completed one-year follow-up. The primary endpoint is defined as the major adverse cardiac event (MACE) at 12 months, a composite endpoint including all-cause death, target lesion revascularization, target vessel revascularization, and non-fatal myocardial infarction. Results: The incidence of the composite endpoint of MACE at one-year follow-up was comparable between the patients with acute and chronic coronary syndrome who underwent complex PCI (12.4% vs. 7.6%, LogRank p = 0.035). Cox multivariate analysis indicated that ACS is an independent risk factor for death at one-year follow-up. Additionally, age and comorbidities, such as heart failure and chronic kidney disease, along with procedural factors, including lesion length and pre-procedural diameter stenosis, are independent predictors of death in patients with complex lesions. Independent risk factors for MACE at one-year follow-up include age, heart failure, previous PCI, in-stent restenosis, and pre-procedural diameter stenosis. Conclusions: The prognosis of patients with acute and chronic coronary syndrome in the annual follow-up is comparable in the context of cardiovascular events. The clinical presentation of ACS is an independent risk factor for all-cause death. Full article
(This article belongs to the Section Cardiovascular Medicine)
Show Figures

Figure 1

12 pages, 1860 KiB  
Article
The Usefulness of Soluble ST2 Concentration in Heart Failure with Reduced Ejection Fraction to Predict Severe Impairment in Exercise Capacity Assessed in Cardiopulmonary Exercise Testing
by Magdalena Dudek, Marta Kałużna-Oleksy, Filip Sawczak, Agata Kukfisz, Aleksandra Soloch, Jacek Migaj, Maciej Lesiak and Ewa Straburzyńska-Migaj
Biomedicines 2025, 13(1), 60; https://doi.org/10.3390/biomedicines13010060 - 30 Dec 2024
Viewed by 1032
Abstract
Background/Objectives: Heart failure (HF) constitutes a complex clinical syndrome that is highly prevalent worldwide, comprises a serious prognosis, and results in a reduced quality of life. Exercise capacity is one of the most significant parameters involved in the prognosis in HF patients. [...] Read more.
Background/Objectives: Heart failure (HF) constitutes a complex clinical syndrome that is highly prevalent worldwide, comprises a serious prognosis, and results in a reduced quality of life. Exercise capacity is one of the most significant parameters involved in the prognosis in HF patients. Our objective was to evaluate the relationship between the selected cardiopulmonary exercise testing (CPET) parameters and the concentration of novel biomarker sST2 in a group of patients with heart failure with reduced ejection fraction (HFrEF). Methods: A group of 135 patients with HFrEF was enrolled in this prospective cohort study. Patients were in the stable phase of the disease in the prior 4 weeks and received optimal medical treatment. Clinical and biochemical parameters were investigated. All patients performed maximal CPET. Results: The mean (SD) concentration of sST2 was 45.5 ± 39.2 ng/mL. Based on the CPET results, the cut-off value (52.377 ng/mL) was established, optimal for the discrimination of relative peakVO2 < 12 mL/kg/min. Patients were divided into two groups according to sST2 cut-off values determined with an ROC curve (AUC 0.692, 95% CI: 0.567–0.816). The mean relative peakVO2 in patients with higher sST2 was 14.5 ± 4.6 mL/kg/min, while in the second group, it was 17.6 ± 5.2 (p = 0.002). In the sST2 ≥ 52.377 ng/mL group, 55.6% of patients achieved VO2 < 50%. Subjects with lower sST2 values obtained higher values of PETCO2 (p < 0.001) and higher values of pulse O2 (p = 0.01). VE/VCO2slope (p = 0.002) was higher in patients with increased sST2 concentration. Conclusions: The concentration of sST2 protein is substantially associated with the clinical severity of heart failure with reduced left ventricular ejection fraction assessed by functional capacity through CPET. Full article
Show Figures

Graphical abstract

11 pages, 851 KiB  
Article
Comparative Short-Term Outcomes of Double-Kissing Culotte and Culotte Techniques in Acute Coronary Syndrome from the Lower Silesia Culotte Bifurcation Registry
by Mateusz Barycki, Adrian Włodarczak, Szymon Włodarczak, Maciej Pęcherzewski, Piotr Włodarczak, Artur Jastrzębski, Łukasz Furtan, Katarzyna Giniewicz, Adrian Doroszko, Piotr Rola and Maciej Lesiak
J. Clin. Med. 2024, 13(23), 7392; https://doi.org/10.3390/jcm13237392 - 4 Dec 2024
Cited by 2 | Viewed by 1026
Abstract
Background/Objectives: The double-kissing (DK) culotte technique is a modification of the culotte technique that employs initial kissing balloon inflation after first stent implantation. The DK culotte technique may improve strut apposition and procedural outcomes; however, data on its efficacy and safety remain limited. [...] Read more.
Background/Objectives: The double-kissing (DK) culotte technique is a modification of the culotte technique that employs initial kissing balloon inflation after first stent implantation. The DK culotte technique may improve strut apposition and procedural outcomes; however, data on its efficacy and safety remain limited. This study aimed to investigate the short-term outcomes of bifurcation percutaneous coronary intervention (PCI) using the DK culotte technique compared with those of the culotte technique in patients with acute coronary syndrome (ACS). Methods: This two-center, observational, retrospective study included patients with ACS. Out of 12,132 screened patients, 117 and 122 underwent DK culotte and culotte PCIs, respectively, with 117 and 57 patients remaining after propensity score matching. The primary endpoint was 1-year target lesion failure (TLF), which included cardiovascular death, target vessel myocardial infarction or clinically indicated target lesion revascularization (TLR). Secondary endpoints included major adverse cardiac events (MACEs) comprising myocardial infarction, cardiac death, and TLR; contrast medium amount (mL); and cumulative radiation dose (mGy). Results: At 1 year, TLF occurred in 7% and 12% of the DK culotte and culotte groups, respectively (p = 0.17). No significant differences were observed in MACEs between the groups (13% DK culotte vs. 19% culotte; p = 0.12). Additionally, the DK culotte technique did not cause higher contrast medium usage or cumulative radiation dosage. Conclusions: No statistically significant differences were found in TLF and MACE reduction between ACS patients treated with the DK culotte technique and the culotte technique. The observed trend favoring the DK culotte needs further validation in prospective studies. Full article
Show Figures

Figure 1

13 pages, 643 KiB  
Article
E-Selectin and Asymmetric Dimethylarginine Levels in Adult Cyanotic Congenital Heart Disease: Their Relation to Biochemical Parameters, Vascular Function, and Clinical Status
by Sonia Alicja Nartowicz, Ludwina Szczepaniak-Chicheł, Dawid Lipski, Izabela Miechowicz, Agnieszka Bartczak-Rutkowska, Marcin Gabriel, Maciej Lesiak and Olga Trojnarska
Cells 2024, 13(17), 1494; https://doi.org/10.3390/cells13171494 - 5 Sep 2024
Cited by 2 | Viewed by 1268
Abstract
Background and Aim: Patients with cyanosis secondary to congenital heart disease (CHD) are characterized by erythrocytosis and increased blood viscosity, which contribute to endothelial dysfunction, increased arterial stiffness, and impaired vascular function, which may affect the final clinical presentation. Asymmetric dimethylarginine (ADMA) and [...] Read more.
Background and Aim: Patients with cyanosis secondary to congenital heart disease (CHD) are characterized by erythrocytosis and increased blood viscosity, which contribute to endothelial dysfunction, increased arterial stiffness, and impaired vascular function, which may affect the final clinical presentation. Asymmetric dimethylarginine (ADMA) and e-selectin (e-sel) are valuable biomarkers for endothelial and vascular dysfunction. Their concentration levels in blood serum have the potential to be an accessible tool that reflects the severity of the disease. We aimed to assess e-sel and ADMA levels and their relationship with the clinical status and endothelial and vascular function. Methods: A cross-sectional study, including 36 adult CHD cyanotic patients [(17 males) (42.3 ± 16.3 years)] with an arterial blood oxygen saturation less than 92% and 20 healthy controls [(10 males) (38.2 ± 8.5 years)], was performed. All the patients underwent a clinical examination, blood testing, and cardiopulmonary tests. Their endothelial function was assessed using the intima media thickness and flow-mediated dilatation. Vascular function, using applanation tonometry methods, was determined using the aortic systolic pressure, aortic pulse pressure, augmentation pressure, augmentation index, pulse pressure amplification, and pulse wave velocity. Results: The concentrations of e-sel and ADMA were significantly higher in the patients with CHD. The E-sel levels correlated positively with red blood cells, hemoglobin concentration, hematocrit, and augmentation pressure; they correlated negatively with blood oxygen saturation, the forced expiratory one-second volume, forced vital capacity, and oxygen uptake. The ADMA levels were found to correlate only with age. Conclusions: The E-sel level, unlike ADMA concentration, reflects the severity of erythrocytosis and hypoxia and, thus, the physical status of patients with cyanotic CHD. Full article
Show Figures

Figure 1

16 pages, 6015 KiB  
Review
Coronary Artery Aneurysm or Ectasia as a Form of Coronary Artery Remodeling: Etiology, Pathogenesis, Diagnostics, Complications, and Treatment
by Patrycja Woźniak, Sylwia Iwańczyk, Maciej Błaszyk, Konrad Stępień, Maciej Lesiak, Tatiana Mularek-Kubzdela and Aleksander Araszkiewicz
Biomedicines 2024, 12(9), 1984; https://doi.org/10.3390/biomedicines12091984 - 2 Sep 2024
Cited by 6 | Viewed by 4356
Abstract
Coronary artery aneurysm or ectasia (CAAE) is a term that includes both coronary artery ectasia (CAE) and coronary artery aneurysm (CAA), despite distinct phenotypes and definitions. This anomaly can be found in 0.15–5.3% of coronary angiography. CAE is a diffuse dilatation of the [...] Read more.
Coronary artery aneurysm or ectasia (CAAE) is a term that includes both coronary artery ectasia (CAE) and coronary artery aneurysm (CAA), despite distinct phenotypes and definitions. This anomaly can be found in 0.15–5.3% of coronary angiography. CAE is a diffuse dilatation of the coronary artery at least 1.5 times wider than the diameter of the normal coronary artery in a patient with a length of over 20 mm or greater than one-third of the vessel. CAE can be further subdivided into diffuse and focal dilations by the number and the length of the dilated vessels. Histologically, it presents with extensive destruction of musculoelastic elements, marked degradation of collagen and elastic fibers, and disruption of the elastic lamina. Conversely, CAA is a focal lesion manifesting as focal dilatation, which can be fusiform (if the longitudinal diameter is greater than the transverse) or saccular (if the longitudinal diameter is smaller than the transverse). Giant CAA is defined as a 4-fold enlargement of the vessel diameter and is observed in only 0.02% of patients after coronary. An aneurysmal lesion can be either single or multiple. It can be either a congenital or acquired phenomenon. The pathophysiological mechanisms responsible for the formation of CAAE are not well understood. Atherosclerosis is the most common etiology of CAAE in adults, while Kawasaki disease is the most common in children. Other etiological factors include systemic connective tissue diseases, infectious diseases, vasculitis, congenital anomalies, genetic factors, and idiopathic CAA. Invasive assessment of CAAE is based on coronary angiography. Coronary computed tomography (CT) is a noninvasive method that enables accurate evaluation of aneurysm size and location. The most common complications are coronary spasm, local thrombosis, distal embolization, coronary artery rupture, and compression of adjacent structures by giant coronary aneurysms. The approach to each patient with CAAE should depend on the severity of symptoms, anatomical structure, size, and location of the aneurysm. Treatment methods should be carefully considered to avoid possible complications of CAAE. Simultaneously, we should not unnecessarily expose the patient to the risk of intervention or surgical treatment. Patients can be offered conservative or invasive treatment. However, there are still numerous controversies and ambiguities regarding the etiology, prognosis, and treatment of patients with coronary artery aneurysms. This study summarizes the current knowledge about this disease’s etiology, pathogenesis, and management. Full article
Show Figures

Figure 1

15 pages, 3426 KiB  
Article
Drug-Eluting Balloons and Drug-Eluting Stents in Diabetic Patients Undergoing Percutaneous Coronary Intervention Due to Restenosis—DM-Dragon Registry
by Piotr Niezgoda, Michał Kasprzak, Jacek Kubica, Łukasz Kuźma, Rafał Januszek, Sylwia Iwańczyk, Brunon Tomasiewicz, Jacek Bil, Mariusz Kowalewski, Miłosz Jaguszewski, Maciej Wybraniec, Krzysztof Reczuch, Sławomir Dobrzycki, Stanisław Bartuś, Maciej Lesiak, Mariusz Gąsior, Rafał Wolny, Adam Witkowski, Robert Gil, Bernardo Cortese, Fabrizio D’Ascenzo, Wojciech Wojakowski and Wojciech Wańhaadd Show full author list remove Hide full author list
J. Clin. Med. 2024, 13(15), 4464; https://doi.org/10.3390/jcm13154464 - 30 Jul 2024
Cited by 1 | Viewed by 1655
Abstract
Background: The rate of in-stent restenosis (ISR) is decreasing; however, it is still a challenge for contemporary invasive cardiologists. Therapeutic methods, including drug-eluting balloons (DEBs), intravascular lithotripsy, excimer laser coronary atherectomy, and imaging-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES), have [...] Read more.
Background: The rate of in-stent restenosis (ISR) is decreasing; however, it is still a challenge for contemporary invasive cardiologists. Therapeutic methods, including drug-eluting balloons (DEBs), intravascular lithotripsy, excimer laser coronary atherectomy, and imaging-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES), have been implemented. Patients with diabetes mellitus (DM) are burdened with a higher risk of ISR than the general population. Aims: DM-Dragon is aimed at evaluating the clinical outcomes of ISR treatment with DEBs vs. DES, focusing on patients with co-existing diabetes mellitus. Methods: The DM-Dragon registry is a retrospective study comprising data from nine high-volume PCI centers in Poland. A total of 1117 patients, of whom 473 individuals had DM and were treated with PCI due to ISR, were included. After propensity-score matching (PSM), 198 pairs were created for further analysis. The primary outcome of the study was target lesion revascularization (TLR). Results: In DM patients after PSM, TLR occurred in 21 (10.61%) vs. 20 (10.1%) in non-diabetic patients, p = 0.8690. Rates of target vessel revascularization (TVR), target vessel myocardial infarction, device-oriented composite endpoint (DOCE), and cardiac death did not differ significantly. Among diabetic patients, the risk of all-cause mortality was significantly lower in the DEB group (2.78% vs. 11.11%, HR 3.67 (95% confidence interval, CI) [1.01–13.3), p = 0.0483). Conclusions: PCI with DEBs is almost as effective as DES implantation in DM patients treated for ISR. In DM-Dragon, the rate of all-cause death was significantly lower in patients treated with DEBs. Further large-scale, randomized clinical trials would be needed to support these findings. Full article
(This article belongs to the Section Cardiology)
Show Figures

Figure 1

9 pages, 210 KiB  
Article
Safety and Effectiveness of Coronary Sinus Reducer in the Therapy of Refractory Angina Pectoris—Mid-Term Results of the Real-Life Cohort
by Szymon Włodarczak, Piotr Rola, Artur Jastrzębski, Karol Turkiewicz, Andrzej Korda, Piotr Włodarczak, Mateusz Barycki, Jan Jakub Kulczycki, Łukasz Furtan, Adrian Włodarczak and Maciej Lesiak
J. Clin. Med. 2024, 13(15), 4413; https://doi.org/10.3390/jcm13154413 - 28 Jul 2024
Cited by 3 | Viewed by 1873
Abstract
Background: Despite continuous improvements in revascularization techniques, refractory angina without potential revascularization options remains a relevant clinical issue with significant impact on the patient’s quality of life. Recently, a novel device, the Coronary Sinus Reducer (CSR), has been introduced into clinical practice as [...] Read more.
Background: Despite continuous improvements in revascularization techniques, refractory angina without potential revascularization options remains a relevant clinical issue with significant impact on the patient’s quality of life. Recently, a novel device, the Coronary Sinus Reducer (CSR), has been introduced into clinical practice as a therapeutic option for patients with disabling angina pectoris. In this single-center, observational study, we evaluated the mid-term (3-month) safety and efficacy of the CSR in a real-world cohort. Methods: The study population consisted of 55 patients with refractory angina without potential revascularization options, who were predominantly men (87.3%) with a high cardiovascular risk factor burden and advanced angina (baseline CCS angina class 3.15 ± 0.6). In terms of procedure safety, all patients underwent successful device deployment with only one periprocedural complication. Results: At the 3-month follow-up, we observed a statistically significant improvement in angina control measured CCS class and SAQ-7 total questionnaire along with increased abolition of physical limitation—6-MWT (233.3 ± 107.1 vs. 305.2 ± 126.8; p < 0.0001). Additionally, we observed significant improvement in terms of quality of life measurements SF-36, the EQ-5D-5L questionnaire, and the EQ-VAS. Conclusions: Our real-world data suggest that CSR implantation is a relatively safe procedure and appears to be particularly effective in relieving angina symptoms and improving quality of life in subjects with refractory angina. Full article
(This article belongs to the Special Issue Clinical Advances in Angina Pectoris)
11 pages, 1032 KiB  
Article
Sex Differences in Fractional Flow Reserve Utilization
by Marta Bujak, Krzysztof Malinowski, Zbigniew Siudak, Anna Ćmiel, Maciej Lesiak, Stanisław Bartuś, Jacek Legutko, Wojciech Wańha, Adam Witkowski, Dariusz Dudek, Mariusz Gąsior, Robert Gil, Marcin Protasiewicz, Jacek Kubica, Piotr Godek, Wojciech Wojakowski and Paweł Gąsior
J. Clin. Med. 2024, 13(14), 4028; https://doi.org/10.3390/jcm13144028 - 10 Jul 2024
Viewed by 1279
Abstract
Background: The literature review shows that female patients are more frequently underdiagnosed or suffer from delayed diagnosis. Recognition of sex-related differences is crucial for implementing strategies to improve cardiovascular outcomes. We aimed to assess sex-related disparities in the frequency of fractional flow [...] Read more.
Background: The literature review shows that female patients are more frequently underdiagnosed or suffer from delayed diagnosis. Recognition of sex-related differences is crucial for implementing strategies to improve cardiovascular outcomes. We aimed to assess sex-related disparities in the frequency of fractional flow reserve (FFR)-guided procedures in patients who underwent angiography and/or percutaneous coronary intervention (PCI). Methods: We have derived the data from the national registry of percutaneous coronary interventions and retrospectively analyzed the data of more than 1.4 million angiography and/or PCI procedures [1,454,121 patients (62.54% men and 37.46% women)] between 2014 and 2022. The logistic regression analysis was conducted to explore whether female sex was associated with FFR utilization. Results: The FFR was performed in 61,305 (4.22%) patients and more frequently in men than women (4.15% vs. 3.45%, p < 0.001). FFR was more frequently assessed in females with acute coronary syndrome than males (27.75% vs. 26.08%, p < 0.001); however, women with chronic coronary syndrome had FFR performed less often than men (72.25% vs. 73.92%, p < 0.001). Females with FFR-guided procedures were older than men (69.07 (±8.87) vs. 65.45 (±9.38) p < 0.001); however. less often had a history of myocardial infarction (MI) (24.79% vs. 36.73%, p < 0.001), CABG (1.62% vs. 2.55%, p < 0.005) or PCI (36.6% vs. 24.79%, p < 0.001) compared to men. Crude comparison has shown that male sex was associated with a higher frequency of FFR assessment (OR = 1.2152–1.2361, p < 0.005). Conclusions: Despite a substantial rise in FFR utilization, adoption in women remains lower than in men. Female sex was found to be an independent negative predictor of FFR use. Full article
(This article belongs to the Section Cardiology)
Show Figures

Figure 1

13 pages, 1213 KiB  
Article
Clinical Factors Affecting Survival in Patients with Congenitally Corrected Transposition of the Great Arteries: A Systematic Review and Meta-Analysis
by Sonia Alicja Nartowicz, Ewelina Jakielska, Piotr Ratajczak, Maciej Lesiak and Olga Trojnarska
J. Clin. Med. 2024, 13(11), 3127; https://doi.org/10.3390/jcm13113127 - 27 May 2024
Cited by 1 | Viewed by 1768
Abstract
Background: Congenitally corrected transposition of the great arteries (cc-TGA) is a defect characterized by arterio-ventricular and atrioventricular disconcordance. Most patients have co-existing cardiac abnormalities that warrant further treatment. Some patients do not require surgical intervention, but most undergo physiological repair or anatomical surgery, [...] Read more.
Background: Congenitally corrected transposition of the great arteries (cc-TGA) is a defect characterized by arterio-ventricular and atrioventricular disconcordance. Most patients have co-existing cardiac abnormalities that warrant further treatment. Some patients do not require surgical intervention, but most undergo physiological repair or anatomical surgery, which enables them to reach adulthood. Aims: We aimed to evaluate mortality risk factors in patients with cc-TGA. Results: We searched the PubMed database and included 10 retrospective cohort studies with at least a 5-year follow-up time with an end-point of cardiovascular death a minimum of 30 days after surgery. We enrolled 532 patients, and 83 met the end-point of cardiovascular death or equivalent event. As a risk factor for long-term mortality, we identified New York Heart Association (NYHA) class ≥III/heart failure hospitalization (OR = 10.53; 95% CI, 3.17–34.98) and systemic ventricle dysfunction (SVD; OR = 4.95; 95% CI, 2.55–9.64). We did not show history of supraventricular arrhythmia (OR = 2.78; 95% CI, 0.94–8.24), systemic valve regurgitation ≥moderate (SVR; OR = 4.02; 95% Cl, 0.84–19.18), and pacemaker implantation (OR = 1.48; 95% Cl, 0.12–18.82) to affect the long-term survival. In operated patients only, SVD (OR = 4.69; 95% CI, 2.06–10.71) and SVR (OR = 3.85; 95% CI, 1.5–9.85) showed a statistically significant impact on survival. Conclusions: The risk factors for long-term mortality for the entire cc-TGA population are NYHA class ≥III/heart failure hospitalization and systemic ventricle dysfunction. In operated patients, systemic ventricle dysfunction and at least moderate systemic valve regurgitation were found to affect survival. Full article
Show Figures

Figure 1

13 pages, 3361 KiB  
Article
Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions
by Adrian Włodarczak, Piotr Rola, Szymon Włodarczak, Marek Szudrowicz, Katarzyna Giniewicz, Magdalena Łanocha, Joanna Jaroszewska-Pozorska, Mateusz Barycki, Łukasz Furtan, Michalina Kędzierska, Piotr Włodarczak, Adrian Doroszko and Maciej Lesiak
J. Pers. Med. 2024, 14(5), 540; https://doi.org/10.3390/jpm14050540 - 17 May 2024
Viewed by 1330
Abstract
Background: The acute coronary syndrome (ACS) continues to be a fundamental indication for revascularization by percutaneous coronary intervention (PCI). Drug-eluting stent (DES) implantation remains a part of contemporary practice but permanent caging of the vascular structure with the metallic stent structure may increase [...] Read more.
Background: The acute coronary syndrome (ACS) continues to be a fundamental indication for revascularization by percutaneous coronary intervention (PCI). Drug-eluting stent (DES) implantation remains a part of contemporary practice but permanent caging of the vascular structure with the metallic stent structure may increase the rate of device-related adverse clinical events. As an alternative to classic metallic DESs, the bioresorbable scaffolds (BRSs) have emerged as a temporary vascular support technology. We evaluated the mid-term outcomes of two generations of bioresorbable scaffolds—Absorb (Abbott-Vascular, Chicago, IL, USA) and Magmaris (Biotronik, Germany)—in patients with non-ST-elevation ACS. Methods: The study cohort consisted of 193 subjects after Magmaris implantation and 160 patients following Absorb implantation in large-vessel lesions. Results: At 2 years, a significantly lower rate of a primary outcome (cardiac death, myocardial infarction, stent thrombosis) was observed with Magmaris (5.2% vs. 15%; p = 0.002). In addition, we observed a significantly lower rate of MI in the target vessel (2.6% vs. 9.4%; p = 0.009) and a lower rate of scaffold thrombosis (0% vs. 3.7%; p = 0.008). The TLF rate between the two groups was not significantly different. Conclusion: Magmaris demonstrated a good safety profile and more favorable clinical outcomes when compared to Absorb in patients with non-ST-elevation ACS. Full article
(This article belongs to the Special Issue New Perspectives and Current Challenges in Myocardial Infarction)
Show Figures

Figure 1

12 pages, 1536 KiB  
Article
A Twenty-Year Follow-Up of Adults with Ebstein Anomaly with Special Focus on Supraventricular Arrhythmias, Supraventricular Arrhythmias and Effectiveness of Catheter Ablation in 20-Year Follow-Up of Adults with Ebstein Anomaly
by Sonia Alicja Nartowicz, Aleksandra Ciepłucha, Michał Waśniewski, Izabela Miechowicz, Justyna Rajewska-Tabor, Agnieszka Bartczak-Rutkowska, Maciej Lesiak, Małgorzata Pyda and Olga Trojnarska
J. Clin. Med. 2024, 13(7), 2039; https://doi.org/10.3390/jcm13072039 - 1 Apr 2024
Cited by 1 | Viewed by 1442
Abstract
Background: Ebstein anomaly (EA) is a rare congenital heart disease characterized by the apical displacement of the tricuspid leaflets, creating an enlarged functional right atrium. Supraventricular arrhythmias (SVA) are common, and catheter ablation remains challenging. SVA is considered a risk factor for [...] Read more.
Background: Ebstein anomaly (EA) is a rare congenital heart disease characterized by the apical displacement of the tricuspid leaflets, creating an enlarged functional right atrium. Supraventricular arrhythmias (SVA) are common, and catheter ablation remains challenging. SVA is considered a risk factor for sudden cardiac death in this population. Still, there are very few real-life data on the impact of SVA treated invasively or conservatively on a patient’s prognosis. We aimed to analyze the incidence of SVA in adults with EA, evaluate the effectiveness of catheter ablation, and analyze the impact of SVA and catheter ablation on survival in this population. Methods and results: 71 pts (median age 53 years; range 24–84 years) with EA were evaluated retrospectively from 1988 to 2020. Forty patients (56.3%) had SVA, and eighteen of them (45.0%) required at least one catheter ablation (35 procedures in total). Indications for ablation were mostly intra-atrial reentrant tachycardia (IART) and atrioventricular reentrant tachycardia (AVRT) (14 pts [77.8% and 9 pts [50.0%], respectively. IART and AVRT coexisted in nine pts. One patient suffered from persistent atrial fibrillation. Procedural effectiveness was reported in 28 (80%) cases; over a longer follow-up (mean 12.6 ± 5.4 years), only eight (44.4%) patients were completely free from SVA after the first ablation. In total, 10 patients (14%) died due to cardiovascular events. There was no difference in survival between patients with or without SVA (p = 0.9) and between ablated and non-ablated EA individuals (p = 0.89). Conclusions: Supraventricular arrhythmia is frequent in adults with Ebstein anomaly. Patients often require more than one catheter ablation but eventually become free from arrhythmias. The imaging parameters assessed by echocardiography or cardiac magnetic resonance do not seem to be associated with ablation outcomes. The impact of supraventricular arrhythmia itself or treatment with radiofrequency ablation is questionable and should be thoroughly investigated in this population. Full article
(This article belongs to the Section Cardiology)
Show Figures

Figure 1

8 pages, 5262 KiB  
Case Report
Cardiac Post-Chest Radiotherapy Complications in a 50-Year-Old Patient with Hodgkin Lymphoma
by Aneta Klotzka, Karolina Sobańska, Sylwia Iwańczyk, Marek Grygier, Patrycja Woźniak, Maciej Błaszyk, Natalia Rozwadowska and Maciej Lesiak
J. Clin. Med. 2023, 12(20), 6506; https://doi.org/10.3390/jcm12206506 - 13 Oct 2023
Viewed by 1857
Abstract
Lymphomas are a group of malignant tumors that originate in the lymphatic system. It is the most common type of blood cancer. It affects the lymph nodes, spleen, bone marrow, blood, and other organs. They can be aggressive or chronic. Hodgkin lymphoma survival [...] Read more.
Lymphomas are a group of malignant tumors that originate in the lymphatic system. It is the most common type of blood cancer. It affects the lymph nodes, spleen, bone marrow, blood, and other organs. They can be aggressive or chronic. Hodgkin lymphoma survival rate is 2 in 100,000 people. Young adults aged 20–30 and people over 50 are most often affected. The prognosis of Hodgkin’s lymphoma is good, with a survival rate of up to 80 percent. Nevertheless, in 20–30 percent of patients who initially respond to treatment, the disease has a tendency to progress. The positive effect of radiotherapy (RT) on patients’ survival rates has been proven in many randomized clinical trials. Although the dose of chest RT has significantly reduced over the years, we still struggle with the long-term complications of post-RT repercussions, mainly because there is no established safe dose of RT affecting the heart. Other complications include earlier onset of coronary artery disease, early and late onset of pericarditis, valve degeneration (predominantly of the left heart), calcification of the aorta and its branches, heart failure, and arrhythmias. One patient can manifest each of the abovementioned complications, as in the present case. That is why choosing the right treatment strategy is crucial. Full article
(This article belongs to the Section Cardiology)
Show Figures

Figure 1

4 pages, 2954 KiB  
Interesting Images
Rapidly Progressive Idiopathic Pulmonary Arterial Hypertension in a Paediatric Patient Treated with Lung Transplantation
by Filip Baszkowski, Weronika Pelczar-Płachta, Nikola Pempera, Sylwia Sławek-Szmyt, Marta Kałużna-Oleksy, Maciej Lesiak and Waldemar Bobkowski
Diagnostics 2023, 13(20), 3185; https://doi.org/10.3390/diagnostics13203185 - 12 Oct 2023
Viewed by 1490
Abstract
Pulmonary arterial hypertension (PAH) is a rare heterogeneous disorder in the paediatric population which is mostly associated with congenital heart disease. The management of paediatric idiopathic PAH (IPAH) is difficult due to insufficient comparative data and depends on the results of evidence-based adult [...] Read more.
Pulmonary arterial hypertension (PAH) is a rare heterogeneous disorder in the paediatric population which is mostly associated with congenital heart disease. The management of paediatric idiopathic PAH (IPAH) is difficult due to insufficient comparative data and depends on the results of evidence-based adult studies with several pulmonary vasodilators, as well as the clinical experiences of paediatric experts. Our aim was to present the case of a 9-year-old girl who underwent several methods of treatment, including pharmacotherapy with a significant reaction to treprostinil, as well as bilateral lung transplantation. The patient’s treatment was distinguished by the fact that the dose escalation was as rapid as that observed in the adult population. Due to the limited current evidence and knowledge, the initiation of treatment for these patients remains an individual choice. On the grounds of the number of non-specific symptoms, the diagnosis of this patient was a long process and based mainly on the differential diagnosis. The purpose of this paper is to study this example in order to highlight the importance of early symptoms and the quick implementation of intensive treatment. The applied methods may be useful in doubtful diagnosis processes and treatment procedures in the paediatric population. Full article
(This article belongs to the Special Issue Critical Care Imaging—2nd Edition)
Show Figures

Figure 1

Back to TopTop